Entrada Therapeutics, Inc.TRDANASDAQ
Loading
Operating Expenses Over TimeStrong
Percentile Rank100
3Y CAGR+22.2%
5Y CAGR+46.4%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+22.2%/yr
Annual compound
5Y CAGR
+46.4%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
6.7x
Strong expansion
Streak
6 yr
Consecutive growthStrong
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $177.32M | +8.3% |
| 2024 | $163.77M | +23.9% |
| 2023 | $132.18M | +35.9% |
| 2022 | $97.25M | +90.2% |
| 2021 | $51.13M | +94.1% |
| 2020 | $26.34M | +122.8% |
| 2019 | $11.82M | - |